High expression of AK1 (Adenylate Kinase 1) has been shown to correlate with poor prognosis of AML patients undergoing chemotherapy, suggesting that it can be used as an independent factor for treatment selection (Qin et al., 2020). This evidence concerns the gene AK1 and acute myeloid leukemia.